Research
Hormonal
Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.
Focus on reducing visceral and ectopic fat through sustainable lifestyle changes, as this is the most effective way to improve insulin sensitivity and prevent Type 2 Diabetes. Prioritize weight management, especially in high-risk groups, as it is the primary driver of the disease.
StrongSupportsVERY_HIGH confidence
Obesity is the most important culprit of insulin resistance... The distribution of fat tissue is the crucial factor to develop insulin resistance... ectopic fat deposition in the liver of obese patients is a very important marker of insulin resistance and glucose deregulation.
Why this rating
Supported by multiple large-scale longitudinal studies, meta-analyses, and consistent epidemiological data cited in the review.
Source
Obesity and diabetes—Not only a simple link between two epidemics
Agata Chobot et al. · Diabetes/Metabolism Research and Reviews · 2018
DOI 10.1002/dmrr.3042
narrative_reviewCited 288×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In Type 1 Diabetes (T1D), obesity and weight gain are increasingly common complications of intensive insulin therapy, contributing to insulin resistance and cardiovascular risk, but GLP-1 agonists and SGLT2 inhibitors show promise in mitigating weight gain.Good
- Gut microbiome composition, specifically the ratio of Firmicutes to Bacteroidetes and the presence of Akkermansia muciniphila, influences obesity and diabetes risk through mechanisms involving short-chain fatty acid production, bile acid metabolism, and gut permeability.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →